Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.
Ki67
breast cancer
luminal-like subtype
progesterone receptor
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
11
2021
accepted:
02
03
2022
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
In luminal-like early breast cancer (BC), the lack of Progesterone Receptor (PR) expression generally correlates with more aggressive behavior but the clinical validity of low PR levels remains a debated issue. The main aim of this retrospective analysis was to assess the survival outcome (Breast cancer specific survival, BCSS) in a cohort of 687 luminal-like HER2 negative early BC patients treated at our Institutions from January 2000 to December 2018, using a sub-classification of tumors in subgroup 1 (PR high/Ki67 low), subgroup 2 (PR high/Ki67 high), subgroup 3 (PR low/Ki67 low), subgroup 4 (PR low/Ki67 high) according to PR and Ki67 values. At a median follow-up of 7 years, BCSS rates were 96.3%, 89%, 86.8% and 85% in the subgroup 1, 2, 3, 4 respectively. Overall, a statistically significant difference in BCSS rates was observed among the 4 subgroups (p=0.0036). On univariate analysis, post-menopause, older age (≥ 50 years), low PR and high Ki67 expression, poorly differentiated grade and size ≥ 2 cm as well as luminal B-like tumors (subgroups 2, 3, 4) were significantly associated with a worse BCSS. Multivariate analysis identified grade, size and subgroup classification of BC as independent prognostic markers of poorer outcome. In particular, subgroups 4, 3 and 2 displayed a significantly higher risk of BC-related death (HR=4.11; p=0.008; HR=3.43; p=0-007; HR=2.57; p=0.020, respectively) when compared to subgroup 1. Our results support the usefulness of PR and Ki67 levels as prognostic markers, corroborating their crucial role in the decision-making process of patients with luminal-like HER2 negative early BC. Clinical application of these parameters should be assessed prospectively.
Identifiants
pubmed: 35419293
doi: 10.3389/fonc.2022.813462
pmc: PMC8996175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
813462Informations de copyright
Copyright © 2022 Diana, Carlino, Buono, Antoniol, Famiglietti, De Angelis, Carrano, Piccolo, De Vita, Ciardiello, Daniele, Arpino and Orditura.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Oncol. 2011 Oct;22(10):2201-7
pubmed: 21335417
Int J Breast Cancer. 2017;2017:1257078
pubmed: 28168058
J Clin Oncol. 2003 May 15;21(10):1973-9
pubmed: 12743151
J Clin Oncol. 2013 Jan 10;31(2):203-9
pubmed: 23233704
PLoS One. 2014 Aug 29;9(8):e95629
pubmed: 25170613
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Semin Oncol. 2020 Aug;47(4):187-200
pubmed: 32546323
Lancet Oncol. 2020 Nov;21(11):1443-1454
pubmed: 33152284
Cancer Invest. 2010 Nov;28(9):978-82
pubmed: 20690804
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
J Clin Oncol. 2007 Oct 20;25(30):4772-8
pubmed: 17876012
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Endocr Relat Cancer. 2019 Feb;26(2):177-185
pubmed: 30407916
BMC Med. 2015 Oct 05;13:254
pubmed: 26437901
Cancer Treat Rev. 2018 Jun;67:78-87
pubmed: 29772460
Ann Oncol. 2013 Mar;24(3):661-8
pubmed: 23022996
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Clin Oncol. 2011 Nov 10;29(32):4273-8
pubmed: 21990413
Br J Cancer. 2007 May 21;96(10):1504-13
pubmed: 17453008
J Clin Oncol. 2016 Mar 20;34(9):927-35
pubmed: 26786933
Clin Breast Cancer. 2015 Jun;15(3):204-11
pubmed: 25600243
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Lancet Oncol. 2011 Nov;12(12):1101-8
pubmed: 22018631
Cancer. 2011 Apr 15;117(8):1595-601
pubmed: 21472707
J Clin Oncol. 2004 May 1;22(9):1769-70
pubmed: 15118010
Breast. 2003 Dec;12(6):362-7
pubmed: 14659106
J Clin Oncol. 2008 Mar 20;26(9):1404-10
pubmed: 18349391
Clin Breast Cancer. 2017 Feb;17(1):41-47
pubmed: 27477822
Oncologist. 2011;16(3):276-85
pubmed: 21339261
J Clin Oncol. 2013 Aug 1;31(22):2783-90
pubmed: 23816962
Hematol Oncol Stem Cell Ther. 2019 Jun;12(2):89-96
pubmed: 30796885
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
J Clin Oncol. 2008 Mar 1;26(7):1059-65
pubmed: 18227529
NPJ Breast Cancer. 2021 Aug 2;7(1):101
pubmed: 34341356
Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):287-91
pubmed: 23060300
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
Breast Cancer Res. 2007;9(1):R6
pubmed: 17239243